Acarbose is an alpha-glucosidase inhibitor approved for the treatment of type 2 diabetic postprandial hyperglycaemia (5); typically used as monotherapy in Asia (6) and as an add-on treatment in the rest of the world. The gene discussed is GAA; the disease is type 2 diabetes mellitus.